Strategies for maximizing clinical effectiveness in the treatment of schizophrenia.
The ultimate clinical objective in the treatment of schizophrenia is to enable affected individuals to lead maximally productive and personally meaningful lives. As with other chronic diseases that lack a definitive cure, the individual's service/recovery plan must include treatment interventions directed towards decreasing manifestations of the illness, rehabilitative services directed towards enhancing adaptive skills, and social support mobilization aimed at optimizing function and quality of life. In this review, we provide a conceptual framework for considering approaches for maximizing the effectiveness of the array of treatments and other services towards promoting recovery of persons with schizophrenia. We discuss pharmacological, psychological, and social strategies that decrease the burden of the disease of schizophrenia on affected individuals and their families while adding the least possible burden of treatment. In view of the multitude of treatments necessary to optimize outcomes for individuals with schizophrenia, effective coordination of these services is essential. In addition to providing best possible clinical assessment and pharmacological treatment, the psychiatrist must function as an effective leader of the treatment team. To do so, however, the psychiatrist must be knowledgeable about the range of available services, must have skills in clinical-administrative leadership, and must accept the responsibility of coordinating the planning and delivery of this multidimensional array of treatments and services. Finally, the effectiveness of providing optimal individualized treatment/rehabilitation is best gauged by measuring progress on multiple effectiveness domains. Approaches for efficient and reliable assessment are discussed.
Tandon
Rajiv
R
Florida Department of Children and Families, Tallahassee, FL 32399, USA.
Targum
Steven D
SD
Nasrallah
Henry A
HA
Ross
Ruth
R
D000223:Adaptation, Psychological; D014150:Antipsychotic Agents / Q000009:adverse effects; D003072:Cognition Disorders / Q000453:epidemiology; D017281:Cost of Illness; D003695:Delivery of Health Care / Q000592:standards; D006285:Health Planning; D006293:Health Promotion; D006304:Health Status; D006801:Humans; D008605:Mental Health Services / Q000458:organization & administration* / Q000592:standards; D011788:Quality of Life / Q000523:psychology; D012559:Schizophrenia / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D055502:Secondary Prevention; D012720:Severity of Illness Index; D012944:Social Support; D013240:Stereotyping; D016896:Treatment Outcome; D014481:United States
D014150:Antipsychotic Agents